MedPath

GLIA, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:3

Trial Phases

1 Phases

Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (100.0%)

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

Phase 2
Active, not recruiting
Conditions
Ocular Graft-versus-host Disease
Interventions
Drug: Placebo
Drug: Pro-ocular™ Topical Gel 1%
First Posted Date
2021-02-24
Last Posted Date
2023-03-24
Lead Sponsor
Glia, LLC
Target Recruit Count
44
Registration Number
NCT04769648
Locations
🇺🇸

BostonSight, Needham, Massachusetts, United States

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

Phase 2
Completed
Conditions
Contact Lens Discomfort
Contact Lens-induced Corneal Disorder
Contact Lens Acute Red Eye
Contact Lens-induced Corneal Fluorescein Staining
Interventions
Drug: CLM2 topical gel
Drug: Placebo topical gel
First Posted Date
2019-06-21
Last Posted Date
2023-03-24
Lead Sponsor
Glia, LLC
Target Recruit Count
30
Registration Number
NCT03994406
Locations
🇺🇸

UC Berkeley Clinical Research Center, Berkeley, California, United States

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Phase 2
Completed
Conditions
Chronic Ocular Graft-versus-host Disease
Interventions
Drug: Pro-ocular™ topical gel
Drug: Placebo topical gel
First Posted Date
2019-06-18
Last Posted Date
2025-05-06
Lead Sponsor
Glia, LLC
Target Recruit Count
33
Registration Number
NCT03990051
Locations
🇺🇸

Massachusetts Eye and Ear Longwood, Boston, Massachusetts, United States

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

Phase 2
Completed
Conditions
Ocular Surface Disease
Interventions
Drug: Placebo
First Posted Date
2016-01-15
Last Posted Date
2023-03-24
Lead Sponsor
Glia, LLC
Target Recruit Count
49
Registration Number
NCT02656394
Locations
🇺🇸

New York Eye & Ear Infirmary of Mount Sinai, New York, New York, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.